In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
Glioblastoma is an aggressive form of brain cancer with no cure, but a new OMRF discovery offers hope.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
OMRF officials brought more than 110 long-time donors together from across the state to celebrate their dedicated supporters at the annual Loyal Donor Society reception.
QBioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer.